Infectious Disease Diagnostic Market Size, Share and Growth Analysis Report - Forecast Trends and Outlook 2026-2030

The infectious disease diagnostics market comprises tests, instruments, and reagents used to identify pathogens including viruses, bacteria, fungi, and parasites. With a 2025 valuation near $27.5 billion, the market spans multiple technology platforms including traditional immunoassays, molecular diagnostics, mass spectrometry, and rapid point-of-care devices. Healthcare providers, diagnostic laboratories, public health agencies, and increasingly decentralized care settings all drive demand for accurate, timely infectious disease testing.

• •Technology segments include molecular diagnostics, immunoassays, POC testing, and microbiology systems
• •End users span hospitals, clinical laboratories, academic institutions, and point-of-care facilities
• •Market value estimated between $26.5B and $28.4B across industry sources in 2025

The rising global burden of infectious diseases, including HIV, tuberculosis, hepatitis, and respiratory infections, continues to expand demand for reliable diagnostic solutions. Advances in molecular technologies, particularly real-time PCR and next-generation sequencing, have dramatically improved test sensitivity, speed, and multiplexing capabilities. The COVID-19 pandemic accelerated investment in infectious disease infrastructure and demonstrated the critical importance of rapid, scalable diagnostics in outbreak response.

• •Aging populations and rising chronic disease prevalence increase susceptibility to infections
• •Expanding healthcare access in emerging markets and greater screening programs boost test volumes
• •Growing awareness of antimicrobial resistance drives demand for rapid, precise pathogen identification

By technology, molecular diagnostics represents the fastest-growing segment due to its superior accuracy and ability to detect a wide range of pathogens simultaneously. Immunoassays remain the largest segment by revenue due to their widespread use and cost-effectiveness. Geographically, North America dominates the market, with the regional segment valued at approximately $8.5 billion in 2025 and projected to reach nearly $15 billion by 2033. Europe and Asia-Pacific follow, with the Asia-Pacific region expected to see accelerated growth driven by improving healthcare infrastructure and rising disease burden.

• •North America leads globally, growing from $8.48B in 2025 to $14.94B by 2033 at 7.34% CAGR
• •Asia-Pacific and Latin America are emerging as high-growth regions due to expanding healthcare access
• •Point-of-care testing segment valued at $13.35B in 2025, reflecting shift toward decentralized diagnostics

What are the recent trends and outlook?

Artificial intelligence and machine learning are increasingly integrated into diagnostic platforms to improve result interpretation, predict disease outbreaks, and optimize laboratory workflows. Multiplex testing capabilities that detect multiple pathogens in a single assay are gaining prominence, particularly for respiratory and gastrointestinal infections. Over the long term, the market is expected to maintain strong growth momentum, potentially exceeding $60 billion by 2034-2035, as technological innovation, pandemic preparedness investments, and the global emphasis on early disease detection continue to shape the diagnostic landscape.

• •AI-powered diagnostics and digital pathology tools are entering clinical workflows for enhanced analysis
• •Home-based and self-collected testing models are expanding, particularly post-pandemic
• •Long-term projections suggest market could reach $62-63B by 2034-2035 across multiple research estimates